Table 3.
Antimicrobial regimens for the patients with A. baumannii BSIs.
| Regimen | No. of | cases | Proper | Improper |
|---|---|---|---|---|
| Ampicillin | 1 | 0.6% | 1 | 0 |
| Pipercillin/tazobactam | 26 | 14.4% | 5 | 21 |
| comb.w/ciprofloxacin | 12 | 6.6% | 1 | 11 |
| comb.w/tigecycline | 2 | 1.1% | 1 | 1 |
| comb.w/colistin | 2 | 1.1% | 2 | 0 |
| 3-, 4- gen. cephalosporins | 20 | 11.0% | 5 | 15 |
| comb.w/ciprofloxacin | 8 | 4.4% | 0 | 8 |
| comb.w/aminoglycosides | 2 | 1.1% | 0 | 2 |
| Carbapenems | 55 | 30.4% | 5 | 50 |
| comb.w/aminoglycosides | 2 | 1.1% | 0 | 2 |
| comb.w/co-trimoxazole | 2 | 1.1% | 1 | 1 |
| comb.w/ciprofloxacin | 9 | 5.0% | 1 | 8 |
| comb.w/colistin | 10 | 5.5% | 10 | 0 |
| Tigecycline | 6 | 3.3% | 5 | 1 |
| comb.w/co-trimoxazole | 1 | 0.6% | 1 | 0 |
| comb.w/fluoroquinolones | 2 | 1.1% | 2 | 0 |
| Colistin | 4 | 2.2% | 4 | 0 |
| Ciprofloxacin | 6 | 3.3% | 4 | 2 |
| Aminoglycosides | 1 | 0.6% | 0 | 1 |
| Co-trimoxazole | 1 | 0.6% | 1 | 0 |
| Not treated* | 9 | 5.0% | 0 | 9 |
| 181 | 49 | 132 |
*
Patients received drugs not-for-Acinetobacter (n = 7) or none due to refusal of treatment (n = 2).